1. Home
  2. Esperoct

Tags : Esperoct

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A
Regulatory

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission

Tuba Khan June 21, 2019

Shots: The approval is based on results from pre-registration clinical programme assessing Esperoct in 270 patients with severe hemophilia A with 5+years of clinical exposure. The authorization covers all 28 European Union member states The marketing authorization follows EMA’s CHMP positive opinion granted on Apr 26, 2019 with its expected launch in European countries in […]Read More

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults
Regulatory

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive

Vartika Singh April 29, 2019

Shots: The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD, IV, q4days) in 270 patients previously treated with severe hemophilia A and more than 5 years of clinical exposure   The study resulted in effective routine prophylaxis in people with severe hemophilia A, efficacious in treatment and control of bleeding episodes […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting